Leinco Technologies

Anti-Mouse CD105 (Endoglin) - Dylight® 488

Product Code:
 
LEI-C919
Product Group:
 
Primary Antibodies
Host Type:
 
Rat
Antibody Isotype:
 
IgG2a κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
MJ7/18
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Applications:
  • Agonism
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Immunofluorescence (IF)
  • Immunohistochemistry (IHC)
  • Immunohistochemistry- Frozen Section (IHC-F)
  • Immunoprecipitation (IP)
  • Life Cell Imaging
  • Western Blot (WB)
Storage:
 
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C919-50ug50 ug£162.00
Quantity:
LEI-C919-250ug250 ug£263.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 488
Format:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Inflamed mouse skin
Long Description:
CD105 (endoglin) is a TGF-β superfamily co-receptor that promotes angiogenesis, is involved in endothelial integrin-mediated mural cell and leukocyte adhesion, antagonizes TGF-β mediated ERK activation, is essential to the immune response of macrophages, regulates trophoblast differentiation and invasion during pregnancy, promotes T-cell proliferation, and regulates differentiation and collagen expression in myofibroblasts1. CD105 is dysregulated in the vasculature of multiple diseases including cancer, preeclampsia, and hereditary hemorrhagic telangiectasia. Additionally, increased soluble CD105 is associated with numerous cardiovascular pathologies and metabolic disorders with some CD105 polymorphisms being associated with increased risk of cardiovascular damage. CD105 is an effective marker of the tumor vasculature and is a target for early cancer diagnosis and antiangiogenic therapies. CD105 is alternatively spliced, resulting in both long (L-endoglin) and short (S-endoglin) forms1. The predominant isoform, L-endoglin, promotes the proliferation and migration of endothelial cells via enhanced ALK1-Smad1/5 signaling and is the presumed isoform when not specified in the literature. In contrast, S-endoglin enhances ALK5-Smad2/3 signaling. Endoglin has specific receptor-ligand interactions between type I and type II TGF-β superfamily receptors when binding TGF-β superfamily ligands. Mouse CD105 has three separate regions of similarity to TGF-β receptor III but does not contain the RGD tripeptide found in human CD1052. MJ7/18 was produced by immunizing rats with inflamed mouse skin and selecting for reactivity with endothelial cells2, 3. MJ7/18 predominantly stains vascular endothelial cells and is a marker of mouse endothelium2, 4.
NCBI Gene:
2022
Target:
CD105

References

1. Pawlak JB, Blobe GC. Dev Dyn. 251(1):137-163. 2022. 2. Ge AZ, Butcher EC. Gene. 138(1-2):201-206. 1994. 3. Berg EL, Goldstein LA, Jutila MA, et al. Immunol Rev. 108:5-18. 1989. 4. Hallmann R, Mayer DN, Berg EL, et al. Dev Dyn. 202(4):325-332. 1995. 5. Charbord P, Oostendorp R, Pang W, et al. Exp Hematol. 30(10):1202-1210. 2002. 6. Rivera LB, Brekken RA. J Cell Biol. 193(7):1305-1319. 2011. 7. Romero D, O'Neill C, Terzic A, et al. Cancer Res. 71(10):3482-3493. 2011. 8. Kruse A, Hallmann R, Butcher EC. Biol Reprod. 61(6):1393-1401. 1999. 9. Redaelli CA, Semela D, Carrick FE, et al. J Hepatol. 40(2):305-312. 2004. 10. Arguello AA, Fischer SJ, Schonborn JR, et al. Neuroscience. 159(3):1003-1010. 2009. 11. Izawa D, Tanaka T, Saito K, et al. Int Immunol. 11(12):1989-1998. 1999. 12. Lidington EA, Rao RM, Marelli-Berg FM, et al. Am J Physiol Cell Physiol. 282(1):C67-74. 2002. 13. Garton KJ, Gough PJ, Philalay J, et al. J Biol Chem. 278(39):37459-37464. 2003. 14. Kinderlerer AR, Pombo Gregoire I, Hamdulay SS, et al. Blood. 113(7):1598-1607. 2009. 15. Marelli-Berg FM, Peek E, Lidington EA, et al. J Immunol Methods. 244(1-2):205-215. 2000. 16. Ahmad SR, Lidington EA, Ohta R, et al. Immunology. 110(2):258-268. 2003. 17. Karmani L, Bouchat V, Bouzin C. Nanomedicine (Lond). 9(13):1923-1937. 2014. 18. Karmani L, Lev?que P, Bouzin C, et al. Nucl Med Biol. 43(7):415-423. 2016. 19. Engelhardt B, Conley FK, Butcher EC. J Neuroimmunol. 51(2):199-208. 1994.